"",1
"",PLCO USER GUIDE
TABLE OF CONTENTS,
1. Introduction ....................................................................................................................................................... 2,
2. General Data Use ................................................................................................................................................ 2,
Missing Codes..................................................................................................................................................... 2,
Questionnaire Follow-up Eligibility ...................................................................................................................... 2,
Merging Data Across Files ................................................................................................................................... 3,
3. Time and Events ................................................................................................................................................. 3,
"Dates and Days (Entry, Exit, And End of Follow-up) ............................................................................................. 3",
Cancer Ascertainment ........................................................................................................................................ 4,
"Stage, ICD-O-2 Codes and Other Cancer Characteristics ...................................................................................... 4",
Diagnostic Procedures and Treatment ................................................................................................................ 4,
Mortality ............................................................................................................................................................ 5,
Deaths From Cancer Without a Confirmed Diagnosis .......................................................................................... 5,
Extended Follow-up ............................................................................................................................................ 5,
4. Protocol Changes ................................................................................................................................................ 5,
Prior Screening Examinations .............................................................................................................................. 5,
Dual Consent ...................................................................................................................................................... 6,
Age Range .......................................................................................................................................................... 6,
Women without Ovaries ..................................................................................................................................... 6,
Screening Changes.............................................................................................................................................. 6,
"CA-125 Assays, Versions 1 and 2 ......................................................................................................................... 7",
Brooklyn and Alabama ........................................................................................................................................ 7,
5. Cancer Site Specific Considerations ..................................................................................................................... 7,
Lung ................................................................................................................................................................... 7,
Colorectal and Colorectal Adenoma .................................................................................................................... 8,
Ovarian .............................................................................................................................................................. 8,
Female Breast..................................................................................................................................................... 9,
Glioma ............................................................................................................................................................... 9,
Head and Neck ................................................................................................................................................... 9,
Hematopoietic .................................................................................................................................................. 10,
Pancreas ........................................................................................................................................................... 10,
Upper Gastrointestinal ..................................................................................................................................... 10,
6. Other Considerations ........................................................................................................................................ 10,
Baseline Questionnaire (BQ) ............................................................................................................................. 10,
Quality Assurance (QA) Exams .......................................................................................................................... 10,
Second Same Site Primary ................................................................................................................................ 10,
Menopause Status ............................................................................................................................................ 11,
7. Acronym Glossary ............................................................................................................................................. 11,